Exploring the Biological Basis for Exercise Neuroprotection in Parkinson's Disease

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of this study is to explore the relationships of exercise on inflammation in the body of older adults and people with Parkinson's disease (PD). This is important research for older adults but is especially important for people with PD because neuroinflammation is the main pathological mechanism that is responsible for neuron cell death in this neurodegenerative disease. As PD is a progressive disease, halting or slowing the degeneration is an important research target. Halting or slowing the disease progress is known as neuroprotection. Exercise is an attractive therapeutic treatment for people with PD as it has a lot of multi-systemic benefits, but also there is a lot of evidence to suggest that it helps improve symptoms and slow the progression of the disease. Exercise has been theorized to decrease inflammation and, therefore, has a lot of promise as a neuroprotective agent in slowing or halting the degeneration in PD. Unfortunately, there is not a lot of research that has looked into the effect of exercise on the biological processes of inflammation. Thus, the purpose of this study is to investigate the biological evidence that underlies the positive effect of exercise in people with PD.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 30
Maximum Age: 85
Healthy Volunteers: t
View:

• 30-85 years old

• Neurologist-diagnosed PD

• Able to participate in 30 minutes of continuous moderate aerobic exercise with 2-3 short breaks per self-report.

• 30-85 years old

• No major medical diagnoses

• Able to participate in 30 minutes of continuous moderate aerobic exercise with 2-3 short breaks per self-report.

Locations
United States
Nevada
Gait and Balance Laboratory, 217 Bigelow Health Sciences Building, UNLV
RECRUITING
Las Vegas
Contact Information
Primary
Merrill Landers, DPT, PhD
merrill.landers@unlv.edu
17028951377
Time Frame
Start Date: 2024-08-29
Estimated Completion Date: 2026-12-30
Participants
Target number of participants: 90
Treatments
Active_comparator: Parkinson Disease
Participants diagnosed with Parkinson disease (PD) will the main arm of the study and will be compared to the control group.
Active_comparator: Control
Older, adults who are age- and sex-matched to the PD participants.
Related Therapeutic Areas
Sponsors
Leads: University of Nevada, Las Vegas

This content was sourced from clinicaltrials.gov